What Does Vaxcyte Do?

Total employees449
HeadquartersSan Carlos
Founded

Vaxcyte (Nasdaq: PCVX) is a vaccine company dedicated to engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is developing broad-spectrum and novel conjugate and protein vaccines to prevent or treat common and deadly invasive bacterial infections. Vaxcyte's approach, leveraging its proprietary cell-free protein synthesis platform, XpressCF™, enables the design and production of complex vaccines that are difficult or impossible to produce with conventional methods. Their pipeline includes candidates targeting pneumococcal disease, Group A Strep, and periodontitis.

Where Is Vaxcyte's Headquarters?

Vaxcyte officeVaxcyte officeVaxcyte officeVaxcyte office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the central hub for Vaxcyte's research and development, clinical operations, corporate strategy, manufacturing process development, and administrative functions.

Notable Features:

Modern laboratory and office spaces designed to foster collaboration and innovation. The facility houses Vaxcyte's proprietary XpressCF™ cell-free protein synthesis platform and related advanced R&D laboratories critical for vaccine design and production.

Work Culture:

A mission-driven, innovative, and collaborative work environment. Employees are focused on scientific excellence and addressing significant unmet medical needs in infectious diseases. The culture emphasizes teamwork, problem-solving, and a fast-paced approach to vaccine development.

HQ Significance:

The San Carlos headquarters is pivotal for Vaxcyte's operations, housing its core scientific talent, leadership team, and the technological infrastructure underpinning its vaccine development programs. Its location in a biotech hub facilitates access to talent, resources, and industry collaborations.

Values Reflected in HQ: The headquarters likely embodies Vaxcyte's commitment to scientific rigor, innovation in vaccine technology, patient impact, and collaboration to tackle challenging global health threats.

Location:

Vaxcyte's global presence is primarily driven through its international clinical trial operations for its vaccine candidates, which often involve sites in multiple countries. The company also engages with global regulatory authorities and may collaborate with international research institutions and partners. Future global presence is anticipated to expand with the potential commercialization of its vaccines worldwide, involving global manufacturing, supply chain, and distribution networks.

Street Address:

825 Industrial Road, Suite 300

City:

San Carlos

State/Province:

California

Country:

USA

Where Else Does Vaxcyte Operate Around the World?

No additional office locations available.

Buying Intent Signals for Vaxcyte

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Vaxcyte? Meet the Executive Team

As of April 2025, Vaxcyte' leadership includes:

Grant Pickering - Chief Executive Officer & Co-founder
Andrew Guggenhime - President & Chief Financial Officer
Jim Wassil - Chief Operating Officer
Jeff Fairman, Ph.D. - Chief Scientific Officer
Halley E. Gilbert, J.D. - Chief Legal Officer & Corporate Secretary
Lubna F. Bhat, Pharm.D. - Chief Business Officer
Annaliesa Anderson, Ph.D., F.A.A.M., F.R.S.B. - Chief Technical Operations Officer
Bill Bergman - Chief Commercial Officer

Who's Investing in Vaxcyte?

Vaxcyte has been backed by several prominent investors over the years, including:

RA Capital Management
Frazier Healthcare Partners
TPG Growth
Abingworth
Longitude Capital
Roche Venture Fund
OrbiMed
Pivotal bioVenture Partners
Medicxi
Viking Global Investors
Janus Henderson Investors

What Leadership Changes Has Vaxcyte Seen Recently?

Hire2
Exits0

Over the past year, Vaxcyte has made strategic additions to its executive team to bolster its technical operations and commercial readiness as its vaccine candidates progress through clinical development. No major C-level departures were publicly noted during this period.

New Appointments:

Bill Bergman, Bill Bergman appointed as Chief Commercial Officer to build out Vaxcyte's commercial capabilities.
Annaliesa Anderson, Ph.D., Annaliesa Anderson, Ph.D., joined Vaxcyte as Chief Technical Operations Officer, bringing extensive experience in vaccine development and manufacturing.

What Technology (Tech Stack) Is Used byVaxcyte?

Discover the tools Vaxcyte uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Vaxcyte Email Formats and Examples

Vaxcyte's email format most likely follows a common corporate structure, typically using an employee's first initial and last name, followed by '@vaxcyte.com'. This is a standard pattern for many companies in the biotech industry.

flast@vaxcyte.com

Format

jdoe@vaxcyte.com

Example

85%

Success rate

What's the Latest News About Vaxcyte?

Vaxcyte, Inc. (GlobeNewswire)May 15, 2024

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study of VAX-31, its Investigational 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults

Vaxcyte announced the dosing of the first participants in its Phase 1/2 clinical study evaluating the safety, tolerability, and immunogenicity of VAX-31, its investigational 31-valent pneumococcal conjugate vaccine candidate, in healthy adults aged 18-64. This marks a significant step in advancing their next-generation PCV program aimed at broader protection against invasive pneumococcal disease....more

Vaxcyte, Inc. (GlobeNewswire)October 30, 2023

Vaxcyte Announces Positive Top-Line Results from the Phase 2 Proof-of-Concept Study of VAX-24, its Lead 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 65 and Older

Vaxcyte reported positive top-line results from its Phase 2 proof-of-concept study of VAX-24 in adults aged 65 and older. The study demonstrated that VAX-24 was well-tolerated and achieved robust immune responses, meeting its primary safety and immunogenicity objectives. These results support VAX-24's potential as a best-in-class, broader-coverage pneumococcal vaccine....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Vaxcyte, are just a search away.